Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1a/1b Open Label Dose-escalation and Expansion Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors

NCT04344795 is registered in ClinicalTrials.gov with Tempest Therapeutics as lead sponsor.

NCT NCT04344795
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04344795 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1a/1b Open Label Dose-escalation and Expansion Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
Lead sponsor
Tempest Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
May 6, 2020
Completion date
September 25, 2024
Enrollment
89 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, endometrial cancer, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, non small cell lung cancer, solid tumor, solid tumors with pik3ca mutation, squamous cell carcinoma of head and neck, urothelial carcinoma